Ammar Sabilarrohman
By Industry Insights Editorial
June 22, 2026
In the rapidly evolving landscape of digital advertising, the pharmaceutical and healthcare sectors have long occupied a unique position. Unlike retail or entertainment, where consumer data is often fluid and readily accessible, healthcare marketing is defined by rigorous regulatory guardrails, patient privacy mandates, and a profound ethical responsibility. As of mid-2026, the industry has reached a critical inflection point: the traditional, single-track reliance on deterministic identity is no longer sufficient.
According to Kevin Dunn, Chief Revenue Officer at Experian, healthcare marketers are now forced to operate within a "mixed-identity ecosystem." This shift is not merely a technical adjustment; it is a fundamental reconfiguration of how brands communicate with patients and healthcare professionals (HCPs) across an increasingly fragmented digital landscape.
The New Reality: Main Facts of the Mixed-Identity Ecosystem
The core challenge facing modern healthcare marketers is the loss of a "universal" signal. In years past, cookies and device IDs provided a cohesive map of user behavior. Today, that map is fractured. A single pharmaceutical campaign might simultaneously traverse environments where identity is highly authenticated, others where it is strictly anonymized, and some where only contextual signals are permitted.
This environment requires a shift in mindset. Marketers can no longer rely on a "one-size-fits-all" targeting strategy. Instead, they must master the ability to coordinate multiple signal types—deterministic, contextual, and aggregated—across three primary workflows: activation, privacy, and measurement.
"Healthcare has always been more constrained than most categories," says Dunn. "But those constraints are becoming more visible as budgets migrate into CTV, point-of-care, publisher-direct, programmatic, and retail media-adjacent environments."
The implication is clear: The ability to manage audience strategy, supply quality, and performance across channels with varying levels of addressability is now the primary differentiator between successful campaigns and those that fail to convert.
Chronology of the Shift: From Cookies to Compliance
To understand why this "mixed-identity" framework has become the industry standard, one must look at the timeline of digital privacy evolution:
- 2020–2022: The Era of Disruption. The industry began experiencing the deprecation of third-party cookies and the introduction of stricter privacy regulations (such as the expansion of state-level privacy laws in the U.S.). Healthcare marketers, accustomed to precise targeting, found their traditional methods of audience construction suddenly blocked.
- 2023–2024: The Testing Phase. As privacy-first browsers and platforms gained market share, marketers experimented with "clean rooms" and walled gardens. During this time, the focus was on finding a "replacement" for the cookie, but many realized that a singular replacement was not on the horizon.
- 2025: The Infrastructure Realization. It became evident that identity is not a static state. The industry shifted its focus from seeking a "golden identifier" to building an infrastructure capable of handling "identity fluidity."
- 2026 (Present): The Maturity of Mixed-Identity. The focus has shifted to operationalizing this complexity. Healthcare brands are now integrating disparate data sources, ensuring that even in the absence of a deterministic match, a campaign can maintain relevance through sophisticated contextual modeling and aggregated measurement.
Supporting Data and Technical Nuances
The complexity of this transition is evidenced by the friction between different stakeholders in the advertising supply chain. Data suggests that while pharmaceutical brands are prioritizing addressability to measure patient outcomes like "script lift," publishers are increasingly restricting data access to maintain user trust and comply with local regulations.
The Conflict of Requirements
- The Marketer’s Need: A pharmaceutical team requires deep visibility into patient/HCP journeys to validate the ROI of their high-value campaigns.
- The Publisher’s Constraint: To protect their audiences and adhere to evolving privacy standards, publishers are limiting the availability of identifiers, often offering only cohort-based signals.
- The Measurement Gap: Measurement partners require granular exposure data to prove efficacy, but many platforms have erected "data silos" that prevent the movement of individual-level IDs.
This misalignment means that the "mixed-identity playbook" is not a set of tools, but a philosophy of orchestration. It involves matching the data approach to the specific environment. If a CTV environment is "identity-light," the playbook mandates a pivot to contextual relevance. If a publisher-direct environment allows for first-party data matching, the playbook mandates a secure, tokenized deterministic approach.
Official Perspective: The Experian View
Kevin Dunn emphasizes that the path forward requires a robust infrastructure that doesn’t just manage data, but governs it. "What comes next is not a choice between deterministic and privacy-forward advertising," Dunn notes. "The differentiator will be whether marketers can build data and measurement infrastructure capable of connecting fragmented signals while maintaining compliance, operational flexibility, and trust."
Experian’s approach highlights that clean rooms and tokenization are not silver bullets. Their efficacy is entirely dependent on the governance frameworks surrounding them. Without interoperability—the ability for insights to move cleanly across different partners and workflows—these advanced tools remain isolated pockets of data rather than cohesive marketing assets.
Implications: The Future of Healthcare Advertising
The shift to a mixed-identity model has profound implications for how healthcare brands will function in the coming years.
1. Supply Quality as a Foundational Metric
In the past, "reach" was the primary KPI. Now, "supply quality" is the prerequisite for all other measurements. If a marketer cannot verify that an ad ran in a brand-safe, compliant, and transparent environment, the downstream measurement of patient engagement or provider influence is essentially worthless. This has elevated the importance of publisher-direct deals and curated supply paths, as they provide a "defensible foundation" for reporting.
2. The End of Data Monopolies
The era of relying on a single data partner or a single platform for full-funnel visibility is coming to an end. Marketers are moving toward a multi-partner ecosystem where data is linked securely through neutral, third-party environments. This requires a higher level of technical literacy within marketing teams, who must now understand the interplay between API-driven data transfers and encrypted identity matching.
3. Compliance as a Competitive Advantage
Rather than viewing privacy regulations as a hurdle, the most successful brands are adopting them as a baseline for brand trust. By building infrastructure that respects patient and HCP privacy by design—using tokenization and aggregated insights—these companies are future-proofing their operations against further regulatory tightening.
4. Operational Flexibility
The "mixed-identity" reality rewards agility. Brands that can quickly switch their measurement tactics based on the "signal strength" of a specific channel will be the ones that capture the most accurate data. This requires an "always-on" approach to campaign testing, where the data team, the media team, and the compliance team work in lockstep to adjust strategies as platform environments change.
Conclusion: Bridging the Gap
As we move through the second half of 2026, the narrative of healthcare advertising is clear: we are living in a world of limited, fragmented, and heterogeneous signals. The marketers who succeed will be those who stop fighting the loss of the "old way" of targeting and start embracing the "new way" of orchestration.
The mixed-identity playbook is ultimately a story about trust. By aligning the technical approach to the specific constraints of the environment—using deterministic data where appropriate and privacy-safe, aggregated insights where necessary—healthcare marketers can continue to deliver critical information to patients and providers. The future belongs to those who can connect these fragmented dots into a coherent, compliant, and measurable picture, ensuring that healthcare marketing remains both effective and ethically sound in an increasingly complex digital world.
Nana Muazin
Asro
